Lacosamide

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Also Known As:

N-benzyl-2-acetamido-3-methoxypropionamide; N-benzyl-AcMeOPrNH2; Vimpat; N benzyl 2 acetamido 3 methoxypropionamide; N benzyl AcMeOPrNH2; Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-

Networked: 736 relevant articles (142 outcomes, 203 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 140
- Amides: 2487
  - Acetamides: 21
    - Lacosamide: 736
- Carboxylic Acids: 986
  - Acyclic Acids
    - Acetates: 5093
      - Acetamides: 21
        Lacosamide: 736

Experts

1.	Doty, Pamela: 17 articles (12/2017 - 01/2007)
2.	Stöhr, Thomas: 13 articles (10/2012 - 01/2006)
3.	De Backer, Marc: 12 articles (12/2020 - 12/2010)
4.	Rosenow, Felix: 11 articles (01/2024 - 03/2009)
5.	Toledo, Manuel: 9 articles (12/2021 - 11/2013)
6.	Biton, Victor: 9 articles (12/2019 - 02/2007)
7.	Park, Ki Duk: 8 articles (12/2022 - 11/2009)
8.	Faught, Edward: 8 articles (12/2021 - 03/2012)
9.	Ben-Menachem, Elinor: 8 articles (01/2021 - 07/2007)
10.	Brandt, Christian: 8 articles (01/2021 - 08/2011)

Related Diseases

1.	Seizures (Absence Seizure) 03/01/2011 - "Patient 2: The add-on medication of lacosamide led to a significant reduction in seizure frequency and to a marked decrease in the mean duration of seizures. " 06/01/2022 - "Lacosamide showed good efficacy for controlling seizures with fewer adverse effects, and therefore may be a good candidate as a first-line medication for the treatment of new-onset CECTS." 07/01/2019 - "Lacosamide treatment appeared beneficial for children and adults experiencing tonic-clonic and myoclonic seizures. " 03/16/2013 - "Combination with lacosamide proved to be significantly less effective in the control of seizures. " 03/01/2011 - "Early lacosamide treatment also dose-dependently reduced the number of spontaneous recurrent seizures following a 6-week waiting period, with 70% reduction at the highest dose tested (50mg/kg); there was also a significant reduction in the number of spikes and the cumulative time spent in seizures. "
2.	Epilepsy (Aura) 01/01/2023 - "Hence, future larger and higher quality clinical studies are needed to further explore both the safety and efficacy of lacosamide in the treatment of epilepsy-associated comorbidities." 01/01/2019 - "Lacosamide is a safe and effective treatment option for patients with epilepsy and psychiatric comorbidities." 10/01/2021 - "This Phase III, long-term, open-label extension (OLE) trial (EP0009; NCT01832038) was conducted to evaluate the long-term safety, tolerability, and efficacy of adjunctive lacosamide (100-400 mg/day) in Chinese and Japanese people with epilepsy (PWE) (16-70 years) who had completed a double-blind, randomized, placebo-controlled trial of adjunctive lacosamide (EP0008; NCT01710657). " 09/01/2019 - "The objective of this study was to evaluate the tolerability and efficacy of lacosamide (LCM) in residential patients at our epilepsy centre. " 07/01/2011 - "Three randomised, multicentre, double-blind, placebo-controlled trials have investigated the efficacy of lacosamide in 1300 adults with epilepsy. "
3.	Status Epilepticus (Complex Partial Status Epilepticus) 01/01/2018 - "Some studies suggest higher efficacy of lacosamide (LCM) in status epilepticus (SE) with higher loading doses; however, this weight-adjusted dose has not been evaluated. " 11/01/2011 - "While lacosamide has been reported as an effective treatment for refractory status epilepticus, there is insufficient evidence for its routine use. " 09/01/2011 - "Experimental data and recent reports suggest that lacosamide could be effective in status epilepticus. " 03/01/2013 - "Lacosamide as a new treatment option in status epilepticus." 08/01/2021 - "Efficacy of lacosamide in neonatal-onset super-refractory status epilepticus: a case report."
4.	Partial Epilepsies (Epilepsy, Partial) 07/01/2014 - "Lacosamide 400 mg/day monotherapy was effective, with a favorable safety profile in patients with focal epilepsy." 06/01/2014 - "Lacosamide represents a useful drug that is effective for a wide range of pediatric refractory focal epilepsy and is well tolerated." 10/01/2023 - "The purpose of this study was to determine the efficacy of lacosamide (LCM) on interictal epileptiform discharges (IEDs) and evaluate the relationships between IEDs and seizure outcome in pediatric patients with focal epilepsy. " 04/01/2019 - "Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system." 01/01/2021 - "Randomised controlled trials of add-on lacosamide in people with drug-resistant focal epilepsy. "
5.	Drug Resistant Epilepsy 01/01/2018 - "Studies suggest that lacosamide may be effective in pediatric patients with refractory epilepsy. " 11/01/2017 - "Lacosamide seems effective and safe for PWID and refractory epilepsy." 12/01/2012 - "The results of this study provide preliminary evidence for the efficacy of lacosamide in children with refractory epilepsy. " 01/01/2018 - "Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: A single-center observational study." 01/01/2023 - "Lacosamide (LCM) is a third-generation antiseizure medication (ASM), and its effect on sleep architecture was supported by a few studies in patients with drug-resistant epilepsy in which LCM was used as an add-on treatment. "

Related Drugs and Biologics

1.	Anticonvulsants (Antiepileptic Drugs)
2.	Levetiracetam (Keppra)
3.	Carbamazepine (Tegretol)
4.	Phenytoin (Dilantin)
5.	Zonisamide (Zonegran)
6.	Topiramate (Topamax)
7.	Oxcarbazepine (Trileptal)
8.	Valproic Acid (Depakote)
9.	Lamotrigine (Lamictal)
10.	eslicarbazepine

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Drug Therapy (Chemotherapy)
4.	Vagus Nerve Stimulation
5.	Relaxation Therapy (Relaxation Technique)